PTK2 and non-small cell lung carcinoma: In conclusion, we demonstrated that two transcripts, RAB32 and THBS1, conferred resistance to osimertinib by activating FAK signaling in NSCLC in vitro and possess potential as diagnostic biomarkers of osimertinib resistance in patients.